Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life
Protein Engineering, Design and Selection · 2025
DOI: 10.1093/protein/gzaf009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2025. Verfasst von Qiu C Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Interleukin-17, Recombinant Fusion Proteins, Immunoglobulin Fc Fragments. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Interleukin-17A (IL-17A) is a cytokine involved in pro-inflammatory responses and tissue regeneration, with potential therapeutic and research applications. However, its short serum half-life limits in vivo use. Here, we report the systematic design of fc-IL-17A fusion proteins for extended half-life. Through computational analysis of 25 design variants using AlphaFold, we found that IL-17A's native N-terminal unstructured region functions as a crucial natural linker that cannot be effectively replaced by artificial sequences. We therefore generated mouse and human fc-IL-17A variants using direct N-terminal fusion without additional linkers. The resulting proteins retain IL-17A's ability to stimulate IL-6 production and erythroid cell growth. Pharmacokinetic analysis confirms that the Fc fusion increases the serum half-life in mice from 1.5 to 13 hours post-subcutaneous injection. This enables tractable experimental use of IL-17A in vivo for studying its role in inflammation and tissue repair. We further perform pharmacokinetics and pharmacodynamics modeling and propose a dosing regimen with reduced frequency of injection for delivering comparable IL-17A activity. This work provides a valuable pharmacological tool for injectable delivery, enabling investigation of IL-17A's biological functions in homeostasis and disease and exploration of its therapeutic potential in tissue regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.
- Cell Design Institute, University of California San Francisco, 600 16th Street, San Francisco, CA 94158, USA.
- Department of Cellular and Molecular Pharmacology, University of California San Francisco, 600 16th Street, San Francisco, CA 94158, USA.
- Department of Molecular, Cell and Cancer Biology, UMASS Chan Medical School, 364 Plantation St, Worcester, MA 01605, USA.
- Wyss Institute for Biologically Inspired Engineering, Harvard University, 201 Brookline Avenue, Boston, MA 02215, USA.
- Laboratory of Systems Pharmacology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA.
ORCID-Profile: Qiu C Wu, Jungmin Lee
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Wu, Q. C., Lee, J., Swaminathan, A., Winward, A., Hwang, Y., Socolovsky, M., Way, J. C., & Klein, A. M. (2025). Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzaf009
Vancouver
Wu QC, Lee J, Swaminathan A, Winward A, Hwang Y, Socolovsky M, et al. Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life. Protein Engineering, Design and Selection. 2025. doi:10.1093/protein/gzaf009
BibTeX
@article{Wu2025,
author = {Wu, Qiu C and Lee, Jungmin and Swaminathan, Aishwarya and Winward, Ashley and Hwang, Yung and Socolovsky, Merav and Way, Jeffrey C and Klein, Allon M},
title = {Linker minimization and characterization of Fc-fused interleukin-17A for increased in vivo half-life},
journal = {Protein Engineering, Design and Selection},
year = {2025},
doi = {10.1093/protein/gzaf009}
}
EUVIMED